Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyoscine butylbromide + dipyrone is a fixed-dose combination of two active pharmaceutical ingredients used primarily for the symptomatic treatment of abdominal pain and cramping associated with gastrointestinal or urinary tract spasms. Hyoscine butylbromide (also known as scopolamine butylbromide) is an antispasmodic and anticholinergic agent that acts as a peripherally acting muscarinic acetylcholine receptor antagonist, leading to smooth muscle relaxation in the gastrointestinal and genitourinary tracts[3][4][5]. Dipyrone (also known as metamizole) is a non-opioid analgesic and antipyretic that provides pain relief by inhibiting prostaglandin synthesis via cyclooxygenase inhibition[1][2][7]. The combination offers both spasmolytic (muscle-relaxing) and analgesic effects. It is widely used in several countries for conditions such as colicky abdominal pain, including those due to irritable bowel syndrome or renal colic. The product is not approved in some regions due to safety concerns related to dipyrone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hyoscine butylbromide + dipyrone.